United States - English - NLM (National Library of Medicine)

nucare pharamaceuticals,inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, usp and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium for oral suspension, usp is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including beta-lactamase – producing strains), or m. catarrhalis (including beta-lactamase-­producing strains) characterized by the following risk factors: - antiba

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amoxicillin; clavulanic acid - film-coated tablet - 500 mg/ 125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor - : antibacterials for systemic use, combinations of penicillins, incl. beta-lactamase inhibitors - - acute bacterial sinusitis (adequately diagnosed) - acute otitis media - acute exacerbations of chronic bronchitis (adequately diagnosed) - community acquired pneumonia - cystitis - pyelonephritis - skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. - bone and joint infections, in particular osteomyelitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

dsm sinochem pharmaceuticals netherlands b.v. - amoxicillin trihydrate; clavulanic acid (as potassium clavulanate, diluted with microcrystalline cellulose (1:1)) - film-coated tablet - 500/125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor - combination of penicillins, incl. beta-lactamase inhibitors - acute bacterial sinusitis (adequately diagnosed) acute otitis media acute exacerbations of chronic bronchitis (adequately diagnosed) community acquired pneumonia cystitis pyelonephritis skin and soft tissue infections in particular cellulitis, animal bites and severe dental abscess with spreading cellulitis. bone and joint infections, in particular osteomyelitis.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension usp and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium for oral suspension usp, 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including beta-lactamase–producing strains), or m. catarrhalis (including beta-lactamase–producing strains) characterized by the following risk fa

Ireland - English - HPRA (Health Products Regulatory Authority)

dsm sinochem pharmaceuticals netherlands b.v. - amoxicillin trihydrate ; clavulanic acid (as potassium clavulanate, diluted with microcrystalline cellulose (1:1)) - film coated tablet - 875/125 milligram - amoxicillin and enzyme inhibitor - : combination of penicillins, incl. beta-lactamase inhibitors - acute bacterial sinusitis (adequately diagnosed) acute otitis media acute exacerbations of chronic bronchitis (adequately diagnosed) community acquired pneumonia cystitis pyelonephritis skin and soft tissue infections in particular cellulitis, animal bites and severe dental abscess with spreading cellulitis. bone and joint infections, in particular osteomyelitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

dsm sinochem pharmaceuticals netherlands b.v. - amoxicillin trihydrate ; clavulanic acid (as potassium clavulanate, diluted : cellulose, microcrystalline(1:1)) - film coated tablet - 500/125 milligram - amoxicillin and enzyme inhibitor - : combination of penicillins, incl. beta-lactamase inhibitors - acute bacterial sinusitis (adequately diagnosed) acute otitis media acute exacerbations of chronic bronchitis (adequately diagnosed) community acquired pneumonia cystitis pyelonephritis skin and soft tissue infections in particular cellulitis, animal bites and severe dental abscess with spreading cellulitis. bone and joint infections, in particular osteomyelitis

Ireland - English - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 1000/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 2000/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

ivowen limited - amoxicillin; clavulanic acid - powder for solution for injection/infusion - 500/100 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (chewable) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium tablets usp, amoxicillin and clavulanate potassium for oral suspension usp, and amoxicillin and clavulanate potassium tablets usp (c